Key facts
- Micot’s last known valuation is $264.6M (May 2021).
- It has raised $100.8M; the latest was Later Stage VC ($13.9M) in Jul 2025.
- Notable investors include SND Ventures Group, Northern Light Venture Capital, Zheshang Venture Capital, Detong Capital, NRL Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Micot
- ·The full record, as it builds
Funding rounds
No funding rounds for Micot are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Micot
Developer of a specific peptide new molecular drug based in Xi'an, China. The company focuses on the clinical research and development of innovative biopharmaceuticals, vaccines and biomolecular drug delivery systems and products, enabling clients to effectively provide medical solutions to major diseases and improve treatment efficiency.
- Sector
- Healthcare
- HQ
- Xi'an, China
- Founded
- 2007
- Employees
- 39
- Website
- micot.cn/
- Ownership
- Privately Held (backing)
Micot doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Micot shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Micot in its N-PORT filings yet. We sweep new filings monthly.